捆绑白丝jk震动捧娇喘视频_国产一级不卡黄色av_久爱视频2019午夜视频_2020国产特级黄色自拍_亚洲熟妇AV日韩熟妇AV_国产精品欧美天美传媒_水蜜桃亚洲成人无码_歐美在線視頻網_日韩在线成人毛片_人妻激情中文字幕

 

 

 

Among them, 21 are over 1 billion varieties, including cefazolin injection, sacubitril valsartan oral regular release form, dapagliflozin oral regular release form, piperacillin injection, sitagliptin oral regular release form, aspirin oral regular release form, acetylcysteine inhaler, famotidine injection, etc.

 

 

 

Data shows that Daggligin Tablets is an oral sodium glucose cotransporter 2 (SGLT2) inhibitor, mainly used for the treatment of type 2 diabetes, heart failure, chronic kidney disease and other adult patients. In recent years, the sales of this product in public medical institutions in China have continued to grow, rapidly increasing from less than 1 billion yuan in 2020 to nearly 4 billion yuan in 2023. The original manufacturer is AstraZeneca, and generic drug companies are launching an impact on the market. Currently, 38 pharmaceutical companies have reported the production of Dapagliflozin tablets under new registration classification, of which 15 have been successfully approved and deemed as having been evaluated.

 

 

 

Acetylcysteine solution for inhalation is a mucolytic agent mainly used to treat respiratory diseases with excessive thick mucus secretion, including acute and chronic bronchitis, emphysema, bronchiectasis, etc. The sales revenue of this product in public medical institutions in China will exceed 2.8 billion yuan in 2023, a year-on-year increase of about 36%. The main manufacturers include Zanbang, Hainan Sida Pharmaceutical, and Hunan Warner Pharmaceutical. In addition, there are currently 34 pharmaceutical companies reporting the production of inhaled acetylcysteine solutions under new registration classification, of which 23 pharmaceutical companies (22 groups) have been successfully approved and deemed to have passed the evaluation.

 

 

 

Piperacillin sodium for injection belongs to the semi synthetic penicillin class of antibiotics and can be used for sepsis, urinary tract infections, respiratory tract infections, biliary tract infections, abdominal infections, pelvic infections, etc. caused by sensitive bacteria. In recent years, the sales of this product in public medical institutions in China have also been continuously increasing, from less than 200 million yuan in 2020 to over 2 billion yuan in 2023, with Suzhou Erye Pharmaceutical, Chengdu Beite Pharmaceutical, and Hunan Kelun Pharmaceutical as the main manufacturers. At present, 24 pharmaceutical companies have submitted supplementary applications for consistency evaluation or reported production under new registration categories for injectable piperacillin sodium. Among them, 15 pharmaceutical companies have successfully passed the evaluation or are deemed to have passed the evaluation.

 

 

 

In addition to piperacillin injection, sales of sitagliptin oral sustained-release form, aspirin oral sustained-release form, acetylcysteine inhaler, and famotidine injection all exceeded 2 billion yuan.

 

 

 

Among the over 1 billion yuan varieties mentioned above, there are many injection varieties. The industry points out that the market for injections is mostly within hospitals, and the effect of increasing the volume of injections by China National Pharmaceutical Group is significant. For injection related enterprises, China National Pharmaceutical Group will be an important opportunity for companies to reshuffle the market.

 

 

 

Data shows that the national procurement of chemical injection drugs has accelerated market reshuffle. In key provinces and cities, the market size of this type of drug in public hospitals exceeded 100 billion yuan annually from 2014 to 2019. However, with the implementation of national procurement winning products, the sales of this type of drug have declined in recent years, falling to 97.8 billion yuan in 2023 and further decreasing by 13.82% in Q1 2024.